Avoro Capital Advisors LLC
13F Reported Value
ⓘ$10.2B
incl. option notional
Equity Holdings
ⓘ$10.2B
Option Notional
ⓘ$13.3M
$0 puts / $13.3M calls
Holdings
32
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Avoro Capital Advisors LLC disclosed 32 positions worth $10.2B in its Form 13F-HR for Q1 2026 — $10.2B in common stock plus $13.3M of put/call option positions (reported at underlying notional value, not premium at risk), led by $UTHR (UNITED THERAPEUTICS Corp) at 15.4% of the equity portfolio, followed by $ASND and $MDGL. During the quarter the fund opened 6 new positions and exited 8 — including a new stake in $CYTK and a full exit from $RNA. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Avoro Capital Advisors LLC’s Form 13F-HR filing with the SEC under CIK 1633313.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 80.1#46
Quality
$1.6B2,630,000 sh - 41.5#1,891
Quality
$1.2B5,062,500 sh - 25.4#2,544
Quality
$951.8M1,818,181 sh - 75.9
Quality
$746.3M2,888,888 sh - —
Quality
$730.3M1,000,000 sh - 74.4
Quality
$670.9M10,699,999 sh - 29.2
Quality
$622.6M7,474,747 sh - 63.9
Quality
$491.7M12,222,222 sh - —
Quality
$454.0M11,430,455 sh - —
Quality
$385.2M3,375,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 UNITED THERAPEUTICS Corp$UTHR | 80.1#46 | $1.6B | 2,630,000 |
 Ascendis Pharma A/S$ASND | 41.5#1,891 | $1.2B | 5,062,500 |
 MADRIGAL PHARMACEUTICALS, INC.$MDGL | 25.4#2,544 | $951.8M | 1,818,181 |
 Krystal Biotech, Inc.$KRYS | 75.9 | $746.3M | 2,888,888 |
 ARGENX SE$ARGX | — | $730.3M | 1,000,000 |
 ARROWHEAD PHARMACEUTICALS, INC.$ARWR | 74.4 | $670.9M | 10,699,999 |
 Kymera Therapeutics, Inc.$KYMR | 29.2 | $622.6M | 7,474,747 |
 Apellis Pharmaceuticals, Inc.$APLS | 63.9 | $491.7M | 12,222,222 |
 Centessa Pharmaceuticals plc$CNTA | — | $454.0M | 11,430,455 |
 Celcuity Inc.$CELC | — | $385.2M | 3,375,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Avoro Capital Advisors LLC's 32 positions.
Showing top 10 of 32 holdings.
Sector Allocation
Healthcare
$10.2B
Full Holdings — Avoro Capital Advisors LLC (Q1 2026)
All 32 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $UTHR | UNITED THERAPEUTICS Corp | $1.6B | 15.4% | +1% | 80.1 |
| 2 | $ASND | Ascendis Pharma A/S | $1.2B | 11.4% | -1% | 41.5 |
| 3 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $951.8M | 9.4% | +1% | 25.4 |
| 4 | $KRYS | Krystal Biotech, Inc. | $746.3M | 7.3% | +0% | 75.9 |
| 5 | $ARGX | ARGENX SE | $730.3M | 7.2% | +1% | — |
| 6 | $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $670.9M | 6.6% | +1% | 74.4 |
| 7 | $KYMR | Kymera Therapeutics, Inc. | $622.6M | 6.1% | +0% | 29.2 |
| 8 | $APLS | Apellis Pharmaceuticals, Inc. | $491.7M | 4.8% | +0% | 63.9 |
| 9 | $CNTA | Centessa Pharmaceuticals plc | $454.0M | 4.5% | -21% | — |
| 10 | $CELC | Celcuity Inc. | $385.2M | 3.8% | +8% | — |
| 11 |  $XENE | Xenon Pharmaceuticals Inc. | $336.0M | 3.3% | +7% | 12.9 |
| 12 |  $GPCR | Structure Therapeutics Inc. | $316.0M | 3.1% | +0% | — |
| 13 |  $TERN | Terns Pharmaceuticals, Inc. | $300.2M | 3.0% | +31% | — |
| 14 |  $VERA | Vera Therapeutics, Inc. | $236.9M | 2.3% | +0% | — |
| 15 |  $RVMD | Revolution Medicines, Inc. | $228.0M | 2.3% | +8% | — |
| 16 |  $CYTK | CYTOKINETICS INC | $219.7M | 2.2% | NEW | 28 |
| 17 |  $OCUL | OCULAR THERAPEUTIX, INC | $104.3M | 1.0% | +14% | 12.8 |
| 18 |  $DMRA | Damora Therapeutics, Inc. | $98.0M | 1.0% | NEW | — |
| 19 |  $QURE | uniQure N.V. | $97.4M | 1.0% | -3% | — |
| 20 |  $TSHA | Taysha Gene Therapies, Inc. | $97.0M | 1.0% | +0% | 4.1 |
| 21 |  $DFTX | Definium Therapeutics, Inc. | $94.5M | 0.9% | NEW | — |
| 22 |  $SLNO | SOLENO THERAPEUTICS INC | $77.0M | 0.8% | -21% | 46.3 |
| 23 |  $ALKS | Alkermes plc. | $42.4M | 0.4% | -14% | — |
| 24 |  $SEPN | Septerna, Inc. | $32.1M | 0.3% | +0% | 44.6 |
| 25 |  $VRDN | Viridian Therapeutics, Inc.\DE | $29.3M | 0.3% | +0% | 30.5 |
| 26 |  $GHRS | GH Research PLC | $25.3M | 0.3% | +0% | — |
| 27 |  $AVTX | Avalo Therapeutics, Inc. | $21.1M | 0.2% | NEW | 4.6 |
| 28 |  $LXEO | Lexeo Therapeutics, Inc. | $10.8M | 0.1% | -43% | — |
| 29 | $UTHRCALL | UNITED THERAPEUTICS Corp | $10.3M | — | NEW | 80.1 |
| 30 |  $WHWK | Whitehawk Therapeutics, Inc. | $9.8M | 0.1% | +0% | 9.6 |
| 31 |  $MNKD | MANNKIND CORP | $5.4M | 0.1% | -50% | 44.4 |
| 32 | $CELCCALL | Celcuity Inc. | $3.0M | — | NEW | — |
New Positions (6)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Avoro Capital Advisors LLC including:
Track Avoro Capital Advisors LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Avoro Capital Advisors LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Avoro Capital Advisors LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Avoro Capital Advisors LLC (SEC CIK: 1633313), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Avoro Capital Advisors LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.